Kyowa Kirin, Kura to Present First Ziftomenib-FLT3 Inhibitor Combination Data at ASH 2026

PUBT · 1d ago
Kyowa Kirin, Kura to Present First Ziftomenib-FLT3 Inhibitor Combination Data at ASH 2026
  • Kyowa Kirin and Kura Oncology will present first ziftomenib-FLT3 inhibitor clinical results at ASH, December 12-15, 2026, in New Orleans.
  • Studies assess ziftomenib with quizartinib in newly diagnosed AML or gilteritinib in relapsed or refractory disease, targeting NPM1/FLT3 co-mutations.
  • Longer-term frontline results for ziftomenib with venetoclax and azacitidine support the ongoing Phase 3 KOMET-017 registrational study.
  • An exploratory analysis supports further investigation of ziftomenib in molecularly defined AML populations beyond NPM1-mutated and KMT2A-rearranged disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyowa Kirin Co. Ltd. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.